BridgeMD
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
EU CTIS ID: 2022-501476-25-00
What this study is testing
To evaluate the efficacy of lebrikizumab when used in combination with TCS treatment, compared with placebo, in participants with moderate-to-severe AD
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have Atopic Dermatitis for at least 6 months if younger than 6 years old or 1 year if older than 6 years.
- 6 months to 6 years old and weigh over 6 kilograms.
- 12 to 18 years old and weigh less than 40 kilograms.
- A parent or legal guardian must be able to sign the consent document and follow to the guidelines of the study.
- And meet other additional conditions at the time of the first visit.
You likely can't join if
- Have been in a similar study with a similar drug or received a forbidden treatment within the last 2 - 8 weeks.
- Be pregnant or breastfeeding.
- Have had previous reaction to the study drug or the ointments or cremes used in this study.
- Have a severe or current infection that requires strong antibiotics.
- Have a history of or have a current disease, or type of illness that your doctor believes could affect your safety.
- Have an addiction to drugs or alcohol.
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- Canada
- Argentina
- Australia
- United States
- Mexico
- Brazil
- Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; Canada; Argentina; Australia; United States; Mexico and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.